During the 2019 American Society of Clinical Oncology Annual Meeting, researchers said that, for payers with large populations, the discounted biosimilar pegfilgrastim can produce substantial cost savings that can be applied to offer increased access to supportive care.
Biosimilar pegfilgrastim, of which 2 brands (Mylan’s Fulphila and Coherus BioScience’s Udencya) have become available in the United States recently, is listed at discount of 33% to the reference product, Amgen’s Neulasta.
During the 2019 American Society of Clinical Oncology Annual Meeting (ASCO), researchers said that, for payers with large populations, the discounted biosimilar pegfilgrastim can produce substantial cost savings that can be applied to offer increased access to supportive care.
The research team, from biosimilar developer Sandoz, which is developing its own biosimilar pegfilgrastim, used a cost minimization model based on a hypothetical group of 20,000 patients.1 They used the average selling price, obtained from payment allowance limits in the first quarter of 2019, for prophylaxis of febrile neutropenia for 1 chemotherapy cycle.
The simulation included a calculation of cost minimization per cycle when patients were converted from the reference pegfilgrastim to a biosimilar on a ratio of 10% to 100% and at a discount of 15% to 35%. Expanded access to biosimilar pegfilgrastim was calculated based on budget neutrality.
They found that per-cycle per-patient cost minimization of converting from reference pegfilgrastim to the biosimilar ranged from $702.27, representing a 15% discount, to $1638.63, representing a 35% discount. For the total 20,000 patients, these savings totaled more than $14 million at a 15% discount to $32 million at a 35% discount for a 100% conversion rate. If half of patients were prescribed the biosimilar, savings could range from more than $7 million at the 15% discount to more than 16 million at the 35% discount.
If 100% of patients were prescribed the biosimilar at the 15% discount, an additional 3529 patients could be treated with the savings generated. If half of the patients were prescribed the biosimilar, the savings could be applied to treat 1765 patients at the same discount. Assuming a 35% discount, 50% biosimilar use would produce savings that could allow 5385 patients to be treated.
For payers with sizable populations, say the researchers, biosimilar pegfilgrastim offers an opportunity to provide increased access on a budget-neutral basis.
While the budgetary benefits of biosimilar pegfilgrastim are clear from the payer perspective, patients may continue to have concerns about receiving a biosimilar rather than its reference. Also during the ASCO meeting, another research team published findings that, although a majority of patients with cancer do not believe that more costly drugs work better than cheaper alternatives, they may have residual concerns about cost-saving drugs when used in cancer care.2
The researchers surveyed a sample of 75 patients with cancer in clinics and an infusion center, asking questions about cost and patient participation in decision-making about treatment options. In total, 66% of respondents said that they did not believe that more costly medicines were more effective than less costly ones for the same disease. However, just 60% of that group and 44% of the overall group said that they preferred that their doctor prescribe a cheaper drug for them.
Among respondents who expressed a belief that more expensive drugs are not more effective but wanted to receive a more expensive drug anyway, 8 respondents indicated that they believed cancer to be too serious to take chances, 5 wanted the most expensive drug covered by insurance, and 2 said that they wanted the best possible medication available.
Additionally, 90.67% said that they wanted to be informed if their physician was prescribing a less expensive version of their therapy.
According to the authors, patients have lingering concerns that cost savings may be a proxy for quality, particularly in cancer indications. Overcoming these perceptions will be crucial, they indicate, if cost savings are to be possible.
References
1. Wang W, Balu S, Campbell K. Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (Febrile) neutropenia and expanded access based on budget neutral basis. Presented at: the American Society of Clinical Oncology Annual Meeting 2019; May 31-June 4, 2019; Chicago, Illinois. Abstract 6645.
2. Harvey RD, McGrath M, Cook JW, Dixon MD, Pentz RD. How will the cost of biosimilars affect patients’ willingness to receive them? Presented at: the American Society of Clinical Oncology Annual Meeting 2019; May 31-June 4, 2019; Chicago, Illinois. Abstract e18338.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.